• Je něco špatně v tomto záznamu ?

Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells

MA. Merlos Rodrigo, B. Casar, H. Michalkova, AM. Jimenez Jimenez, Z. Heger, V. Adam

. 2021 ; 11 (-) : 707366. [pub] 20210901

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024024

Purpose: The chick chorioallantoic membrane (CAM) assay can provide an alternative versatile, cost-effective, and ethically less controversial in vivo model for reliable screening of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on neuroblastoma (Nbl) cells in terms of their growth and metastatic potential. Methods: The Nbl UKF-NB-4 cell line was established from recurrent bone marrow metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli. Immunohistochemistry, qRT-PCR, and DNA isolation were performed. Results: Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor. To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation, and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001) inhibitory activity against extravasation to all investigated organs including distal CAM. Conclusions: Taken together, CAM assay could be a helpful and highly efficient in vivo approach for high-throughput screening of libraries of compounds with expected anticancer activities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024024
003      
CZ-PrNML
005      
20211013134058.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2021.707366 $2 doi
035    __
$a (PubMed)34540673
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Merlos Rodrigo, Miguel Angel $u Research Group for Molecular Biology and Nanomedicine, Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia $u Central European Institute of Technology, Brno University of Technology, Brno, Czechia
245    10
$a Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells / $c MA. Merlos Rodrigo, B. Casar, H. Michalkova, AM. Jimenez Jimenez, Z. Heger, V. Adam
520    9_
$a Purpose: The chick chorioallantoic membrane (CAM) assay can provide an alternative versatile, cost-effective, and ethically less controversial in vivo model for reliable screening of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on neuroblastoma (Nbl) cells in terms of their growth and metastatic potential. Methods: The Nbl UKF-NB-4 cell line was established from recurrent bone marrow metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli. Immunohistochemistry, qRT-PCR, and DNA isolation were performed. Results: Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor. To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation, and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001) inhibitory activity against extravasation to all investigated organs including distal CAM. Conclusions: Taken together, CAM assay could be a helpful and highly efficient in vivo approach for high-throughput screening of libraries of compounds with expected anticancer activities.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Casar, Berta $u Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain $u Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Michalkova, Hana $u Research Group for Molecular Biology and Nanomedicine, Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia $u Central European Institute of Technology, Brno University of Technology, Brno, Czechia
700    1_
$a Jimenez Jimenez, Ana Maria $u Research Group for Molecular Biology and Nanomedicine, Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia $u Central European Institute of Technology, Brno University of Technology, Brno, Czechia
700    1_
$a Heger, Zbynek $u Research Group for Molecular Biology and Nanomedicine, Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia $u Central European Institute of Technology, Brno University of Technology, Brno, Czechia
700    1_
$a Adam, Vojtech $u Research Group for Molecular Biology and Nanomedicine, Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia $u Central European Institute of Technology, Brno University of Technology, Brno, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 11, č. - (2021), s. 707366
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34540673 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134055 $b ABA008
999    __
$a ind $b bmc $g 1708163 $s 1144521
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c - $d 707366 $e 20210901 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20211006
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace